Researchers have now come up with a whole vaccine approach that merges cancer genomics with cancer immunotherapy.
Skin Cancer / Melanoma Targets
The removal of a gene involved in the cellular self-cannibalization process of autophagy could provide therapeutic benefit to patients with melanoma.
The addition of a dual targeted combination of a BRAF plus MEK inhibitor to immunotherapy enhanced the effects of the immunotherapy in a mouse model of melanoma.
It may be possible to combat metastatic melanoma in a new way involving a growth factor protein called Nodal. Combining it with some current therapies may help patients who have not responded to standard therapy.
Results from an early-stage clinical trial, and data from a mouse tumor model suggests that adding a second immune checkpoint inhibitor antibody to a combination therapy of irradiation plus anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) antibody immunotherapy could result in more tumor shrinkage.
Interest in emerging intralesional therapies is justified by their strong ablative effects, lack of toxicity, and their stimulation of local and systemic immunological responses in melanoma patients, according to a recent study published in Current Opinion in Oncology.
This slide show features images of melanoma, basal cell carcinoma, squamous cell carcinoma, as well as images of metastatic disease.
A new study shows how to overcome drug resistance after exposure to certain targeted cancer therapies known as RAF and MEK inhibitors.
It seems as though we are seeing more news reports lately on the rising cost of cancer drugs—specifically targeted therapy drugs. Some are even going as far as to ask cancer patients and survivors to sign a petition in hopes of lobbying Congress so that government officials can negotiate lower prices with pharmaceutical companies.
In the largest analysis to date of overall survival (OS) in ipilimumab-treated patients with advanced melanoma, researchers have found there may be a plateau in the survival curve, beginning at approximately 3 years.